Compare Li Auto Inc (LI) vs 10X Genomics Inc (TXG) Price & Performance

Li Auto (LI) trades at $12.95, up 2.05% today, amid mixed technical signals with a bearish overall trend. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle deliveries show modest growth, with 30,468 vehicles delivered in July 2026. Analyst consensus remains divided with a $14.80 price target, suggesting potential upside from current levels despite near-term challenges.

The outlook for LI is cautious with revenue contraction and profitability pressures, though the EV market in China offers long-term growth potential. Key risks include intense domestic competition and execution challenges with new vehicle launches. Investment opportunity exists if the company can stabilize margins and regain growth momentum, supported by analyst optimism for recovery from 2027 onwards.

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.